Response and resistance to lapatinib in HER2-overexpressing breast cancer
HER2 overexpression has been implicated in breast cancer. Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor used in advanced HER2-positive breast cancer patients who have previously progressed on trastuzumab treatment. Recent meta-analysis of several clinical trials showed that lapatinib was i...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Oxford
2014
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.669708 |